Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Synthetic or plant-based cannabis for symptom relief in patients with cancer
This article discusses the evidence available for synthetic and plant-based [...]
FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer
The glutaminase inhibitor, CB-839 has been granted Fast Track designation [...]
Avelumab combination designated a breakthrough therapy by the FDA
The immunotherapy drug avelumab (Bavencio) has been designated a breakthrough [...]
